CL2017002571A1 - Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composición farmacéutica que comprende los mismos. - Google Patents
Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composición farmacéutica que comprende los mismos.Info
- Publication number
- CL2017002571A1 CL2017002571A1 CL2017002571A CL2017002571A CL2017002571A1 CL 2017002571 A1 CL2017002571 A1 CL 2017002571A1 CL 2017002571 A CL2017002571 A CL 2017002571A CL 2017002571 A CL2017002571 A CL 2017002571A CL 2017002571 A1 CL2017002571 A1 CL 2017002571A1
- Authority
- CL
- Chile
- Prior art keywords
- methoxy
- pharmaceutically acceptable
- pyrrole derivatives
- acceptable salts
- pharmaceutical composition
- Prior art date
Links
- OTODBDQJLMYYKQ-UHFFFAOYSA-N 3-methoxy-1h-pyrrole Chemical class COC=1C=CNC=1 OTODBDQJLMYYKQ-UHFFFAOYSA-N 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000000694 effects Effects 0.000 abstract 3
- 230000002496 gastric effect Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 1
- 208000007882 Gastritis Diseases 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 abstract 1
- 108010083204 Proton Pumps Proteins 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008029 eradication Effects 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000000689 peptic esophagitis Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
<p>La presente invención proporciona un derivado de 4-metoxi-pirrol o una sal farmacéuticamente aceptable del mismo, un método de preparación del mismo y una composición farmacéutica que contiene el mismo. Los derivados de 4-metoxi-pirrol o las sales farmacéuticamente aceptables de los mismos según la presente invención no sólo tienen excelente actividad inhibidora de la bomba de protones, actividad de inhibición del daño gástrico y efectos de potenciación de factores defensivos, sino que también tienen una excelente actividad de erradicación contra H. pylori. Por tanto, los derivados de 4-metoxi-pirrol o las sales farmacéuticamente aceptables de los mismos pueden usarse eficazmente para la prevención y el tratamiento de daño gastrointestinal debido a úlcera del tracto gastrointestinal, gastritis, esofagitis por reflujo o H. pylori. Además, los derivados de 4-metoxi-pirrol o las sales farmacéuticamente aceptables de los mismos tienen actividades inhibidoras contra GPCR y por tanto pueden usarse eficazmente para la prevención y el tratamiento de enfermedades mediadas por receptor 5-HT o mediadas por receptor muscarínico de acetilcolina.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150058712 | 2015-04-27 | ||
| KR1020160013588A KR101613245B1 (ko) | 2015-04-27 | 2016-02-03 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002571A1 true CL2017002571A1 (es) | 2018-03-16 |
Family
ID=55916928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002571A CL2017002571A1 (es) | 2015-04-27 | 2017-10-11 | Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composición farmacéutica que comprende los mismos. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10100010B1 (es) |
| EP (1) | EP3197867B1 (es) |
| JP (1) | JP6244498B1 (es) |
| KR (2) | KR101613245B1 (es) |
| CN (1) | CN107001263B (es) |
| AU (1) | AU2016255308B2 (es) |
| CA (1) | CA2977750C (es) |
| CL (1) | CL2017002571A1 (es) |
| CO (1) | CO2017010539A2 (es) |
| DO (2) | DOP2017000230A (es) |
| EC (1) | ECSP17071036A (es) |
| ES (1) | ES2703709T3 (es) |
| HR (1) | HRP20182066T1 (es) |
| HU (1) | HUE042449T2 (es) |
| MA (1) | MA40887B1 (es) |
| MX (1) | MX2017012507A (es) |
| MY (1) | MY193257A (es) |
| NZ (1) | NZ734896A (es) |
| PE (1) | PE20180022A1 (es) |
| PH (1) | PH12017501755B1 (es) |
| PL (1) | PL3197867T3 (es) |
| PT (1) | PT3197867T (es) |
| RS (1) | RS58076B1 (es) |
| RU (1) | RU2663895C1 (es) |
| SA (1) | SA517390127B1 (es) |
| SG (1) | SG11201706877RA (es) |
| SI (1) | SI3197867T1 (es) |
| TN (1) | TN2017000424A1 (es) |
| WO (1) | WO2016175555A2 (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12673023B2 (en) | 2021-05-26 | 2026-07-07 | Daewoong Pharmaceutical Co., Ltd. | Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170113040A (ko) * | 2016-03-25 | 2017-10-12 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염 |
| KR102081920B1 (ko) | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| WO2017164575A1 (en) * | 2016-03-25 | 2017-09-28 | Daewoong Pharmaceutical Co.,Ltd. | Novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine |
| KR102233456B1 (ko) | 2017-05-31 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102233455B1 (ko) * | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| WO2020060213A1 (ko) | 2018-09-19 | 2020-03-26 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
| KR102126576B1 (ko) * | 2018-09-19 | 2020-06-24 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
| PH12022551415A1 (en) * | 2019-12-18 | 2023-11-20 | Daewoong Pharmaceutical Co Ltd | Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine |
| PT4148050T (pt) * | 2020-06-17 | 2025-01-29 | Ildong Pharmaceutical Co Ltd | Novo inibidor da secreção ácida e sua utilização |
| CN112094219B (zh) * | 2020-09-10 | 2022-08-05 | 广东莱佛士制药技术有限公司 | 一种制备钾离子竞争性阻滞剂中间体的方法 |
| WO2022051979A1 (zh) * | 2020-09-10 | 2022-03-17 | 广东莱佛士制药技术有限公司 | 一种制备钾离子竞争性阻滞剂中间体的方法 |
| UA130030C2 (uk) * | 2020-12-18 | 2025-10-15 | Тевун Фармасутікал Ко., Лтд. | Препарат для перорального введення, який містить 1-(5-(2,4-дифлуорфеніл)-1-((3-флуорфеніл)сульфоніл)-4-метокси-1h-пірол-3-іл)-n-метилметанамін |
| EP4356900A4 (en) * | 2021-05-26 | 2025-08-13 | Daewoong Pharmaceutical Co Ltd | NEW INJECTABLE FORMULATION COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE |
| MX2023013984A (es) * | 2021-05-26 | 2023-12-12 | Daewoong Pharmaceutical Co Ltd | Nueva formulacion para inyeccion que comprende 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h- pirrol-3-il)-n-metilmetanamina. |
| TWI892291B (zh) * | 2021-05-26 | 2025-08-01 | 南韓商大熊製藥股份有限公司 | 含有1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺醯基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺之液體醫藥組成物之醫藥容器 |
| KR102556500B1 (ko) * | 2021-11-19 | 2023-07-19 | 하나제약 주식회사 | 피롤 유도체 또는 이의 약학적 또는 식품학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 위장 질환의 예방, 개선 또는 치료용 조성물 |
| WO2023113474A1 (ko) * | 2021-12-15 | 2023-06-22 | 일동제약(주) | 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| WO2023113458A1 (en) * | 2021-12-15 | 2023-06-22 | Ildong Pharmaceutical Co., Ltd. | Novel salt of 1-sulfonyl pyrrole derivative, preparation method thereof and pharmaceutical composition comprising thereof |
| CN118541141A (zh) * | 2021-12-15 | 2024-08-23 | 株式会社大熊制药 | 非苏拉赞注射组合物的剂量方案 |
| KR20230102353A (ko) * | 2021-12-30 | 2023-07-07 | 주식회사 대웅제약 | 삼중음성유방암의 예방 또는 치료용 약학적 조성물 |
| WO2023211843A1 (en) * | 2022-04-25 | 2023-11-02 | Daewoong Pharmaceutical Co., Ltd. | Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions |
| TW202411216A (zh) * | 2022-05-23 | 2024-03-16 | 南韓商日東製藥股份有限公司 | ６－甲氧基吡啶－３－基衍生物之製造方法 |
| KR102975773B1 (ko) * | 2022-05-23 | 2026-06-10 | 일동제약(주) | 6-메톡시피리딘-3-일 유도체의 제조방법 |
| CN117820193A (zh) * | 2022-09-29 | 2024-04-05 | 安徽皓元药业有限公司 | 一种非苏拉赞盐酸盐晶型a及其制备方法 |
| CN115557876A (zh) * | 2022-10-26 | 2023-01-03 | 四川国康药业有限公司 | 一种用于治疗消化性溃疡的3-芳环基磺酰基-1-n-杂吡咯衍生物、其制备方法和用途 |
| KR102938657B1 (ko) * | 2023-02-15 | 2026-03-12 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
| CN119504552B (zh) * | 2023-12-28 | 2026-06-05 | 菏泽皓元医药科技有限公司 | 一种钾离子竞争性阻滞剂中间体及其制备方法 |
| WO2025174041A1 (ko) * | 2024-02-13 | 2025-08-21 | 유노비아 주식회사 | 6-메톡시피리딘-3-일 유도체를 포함하는 위장관 질환의 치료 방법 |
| KR20260020368A (ko) * | 2024-08-02 | 2026-02-11 | 일양약품주식회사 | 4-사이클로프로필 피롤 유도체 및 이의 용도 |
| KR20260082181A (ko) | 2024-11-27 | 2026-06-04 | (주) 팜젠사이언스 | 신규한 피롤 유도체 화합물 및 이를 포함하는 위산분비 억제용 약제학적 조성물 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003040147A1 (en) | 2001-11-08 | 2003-05-15 | Pharmacia & Upjohn Company | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease__________________________________________________________________________________________________________________________ |
| US7186716B2 (en) | 2002-08-12 | 2007-03-06 | Sugen, Inc. | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| AR050902A1 (es) | 2004-04-27 | 2006-12-06 | Glaxo Group Ltd | Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion |
| EP1784400B1 (en) | 2004-08-23 | 2015-01-14 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
| DK1784404T3 (da) | 2004-09-03 | 2012-02-13 | Yuhan Corp | Pyrrolo[2,3-c]pyridinderivater samt fremgangsmåder til deres fremstilling |
| JP5173192B2 (ja) | 2004-09-30 | 2013-03-27 | 武田薬品工業株式会社 | プロトンポンプ阻害薬 |
| EP1799306B1 (en) | 2004-09-30 | 2011-02-23 | F. Hoffmann-La Roche AG | Compositions and methods for treating cognitive disorders |
| KR101115857B1 (ko) * | 2005-08-30 | 2012-04-12 | 다케다 야쿠힌 고교 가부시키가이샤 | 산 분비 억제제로서 1-헤테로시클릴술포닐, 2-아미노메틸,5-(헤테로-) 아릴 치환된 1-ｈ-피롤 유도체 |
| DE102005041246A1 (de) | 2005-08-31 | 2007-03-08 | Basf Coatings Ag | Von Molybän- und Wolframverbindungen freie, Cäsiumverbindungen enthaltende, härtbare Gemische auf der Basis blockierter Polyisocyanate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| WO2007072146A1 (en) | 2005-12-19 | 2007-06-28 | Pfizer Japan Inc. | Chromane substituted benzimidazoles and their use as acid pump inhibitors |
| AU2007247231B2 (en) | 2006-05-04 | 2012-05-31 | Solvay Pharmaceuticals B.V. | Muscarinic agonists to treat impulse control disorders |
| DE102006027229A1 (de) * | 2006-06-09 | 2007-12-20 | Grünenthal GmbH | 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| US8933105B2 (en) | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| WO2008131779A1 (en) | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
| US8993572B2 (en) | 2010-04-22 | 2015-03-31 | Intra-Cellular Therapies, Inc. | Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives |
| JP6292736B2 (ja) * | 2012-11-19 | 2018-03-14 | ジエンス ハンセン ファーマセウティカル カンパニー リミテッド | ピロールスルホンアミド誘導体、その製造法およびその医療用途 |
| JP2016513677A (ja) | 2013-03-15 | 2016-05-16 | アカディア ファーマシューティカルズ インコーポレイテッド | ムスカリンアゴニスト |
| ITBS20130175A1 (it) | 2013-11-22 | 2015-05-23 | Ind Saleri Italo Spa | Gruppo pompa di raffreddamento regolabile con girante regolabile |
| US10040780B2 (en) | 2014-03-03 | 2018-08-07 | The Regents Of The University Of California | Mcl-1 antagonists |
| CN104447191B (zh) | 2014-10-30 | 2016-03-23 | 绵阳达高特新材料有限公司 | 4-溴-1,2-二氢环丁烯并[α]萘化合物及其制备方法 |
| CN104447491B (zh) * | 2014-11-19 | 2017-06-23 | 连云港恒运医药有限公司 | 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途 |
-
2016
- 2016-02-03 KR KR1020160013588A patent/KR101613245B1/ko active Active
- 2016-04-08 KR KR1020160043522A patent/KR101818704B1/ko active Active
- 2016-04-27 EP EP16786741.5A patent/EP3197867B1/en active Active
- 2016-04-27 MY MYPI2017703532A patent/MY193257A/en unknown
- 2016-04-27 JP JP2017531371A patent/JP6244498B1/ja active Active
- 2016-04-27 ES ES16786741T patent/ES2703709T3/es active Active
- 2016-04-27 PH PH1/2017/501755A patent/PH12017501755B1/en unknown
- 2016-04-27 NZ NZ734896A patent/NZ734896A/en unknown
- 2016-04-27 HU HUE16786741A patent/HUE042449T2/hu unknown
- 2016-04-27 WO PCT/KR2016/004411 patent/WO2016175555A2/en not_active Ceased
- 2016-04-27 TN TNP/2017/000424A patent/TN2017000424A1/en unknown
- 2016-04-27 PT PT16786741T patent/PT3197867T/pt unknown
- 2016-04-27 MA MA40887A patent/MA40887B1/fr unknown
- 2016-04-27 SG SG11201706877RA patent/SG11201706877RA/en unknown
- 2016-04-27 CN CN201680003652.8A patent/CN107001263B/zh active Active
- 2016-04-27 HR HRP20182066TT patent/HRP20182066T1/hr unknown
- 2016-04-27 MX MX2017012507A patent/MX2017012507A/es active IP Right Grant
- 2016-04-27 CA CA2977750A patent/CA2977750C/en active Active
- 2016-04-27 PL PL16786741T patent/PL3197867T3/pl unknown
- 2016-04-27 AU AU2016255308A patent/AU2016255308B2/en active Active
- 2016-04-27 US US15/520,518 patent/US10100010B1/en active Active
- 2016-04-27 RU RU2017133866A patent/RU2663895C1/ru active
- 2016-04-27 PE PE2017001632A patent/PE20180022A1/es unknown
- 2016-04-27 RS RS20181555A patent/RS58076B1/sr unknown
- 2016-04-27 SI SI201630148T patent/SI3197867T1/sl unknown
-
2017
- 2017-10-03 DO DO2017000230A patent/DOP2017000230A/es unknown
- 2017-10-10 SA SA517390127A patent/SA517390127B1/ar unknown
- 2017-10-11 CL CL2017002571A patent/CL2017002571A1/es unknown
- 2017-10-13 CO CONC2017/0010539A patent/CO2017010539A2/es unknown
- 2017-10-25 EC ECIEPI201771036A patent/ECSP17071036A/es unknown
-
2021
- 2021-10-18 DO DO2021000213A patent/DOP2021000213A/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12673023B2 (en) | 2021-05-26 | 2026-07-07 | Daewoong Pharmaceutical Co., Ltd. | Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000213A (es) | Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composición farmacéutica que comprende los mismos | |
| MX2019000451A (es) | Compuesto heterociclico utilizado como inhibidor de fgfr. | |
| CL2018002784A1 (es) | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue. | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| CL2019003309A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| CL2019002744A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| UY36674A (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CL2019003294A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| MX2014015185A (es) | Derivados deuterados de ruxolitinib. | |
| CL2018002718A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| DOP2021000001A (es) | Nueva sal de adición de ácido de 1(5(2,4difluorfenil)1((3fluorfenil)sulfonil)4metoxi1hpirrol3il)nmetilmetanamina | |
| CO2018003471A2 (es) | Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue | |
| CL2018002729A1 (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue. | |
| CO2018003369A2 (es) | Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| PE20180412A1 (es) | Compuestos inhibidores de la senalizacion de la via de notch | |
| UY36518A (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| PE20151607A1 (es) | Formulaciones de compuestos organicos | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| MX2019001577A (es) | Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. | |
| CR20160527A (es) | Derivados de carboxamida | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| UY36123A (es) | Derivados de carboxamida |